Full Name
Karim Fizazi, M.D., Ph.D.
Company Name
Gustave Roussy
Bio
Prof. Karim Fizazi is a medical oncologist at Gustave Roussy and full Professor of Oncology at the University of Paris-Saclay specializing in the management of prostate cancer.
To date, Prof. Fizazi has chaired six practice-changing trials in GU oncology, the pivotal denosumab 103 trial, GETUG 13, LATITUDE in 2017 showing the impact of abiraterone in de novo metastatic prostate cancer, the ARAMIS Phase 3 study of darolutamide in non-metastatic castration-resistant prostate cancer, the PEACE-1 trial 2021, and the TRITON-3 trial in 2023 showing the role of rucaparib in mCRPC.
In 2013, Prof. Fizazi established the Prostate Cancer Consortium in Europe (PEACE); and is leading several large European Phase III trials, PEACE-1, PEACE-2 and the ongoing PEACE-4.
Prof. Fizazi is the president of the French Groupe d’Etude des Tumeurs Genito-Urinaires(GETUG). He is the Associate Editor of the European Journal of Cancer and has authored almost 500 scientific publications.
To date, Prof. Fizazi has chaired six practice-changing trials in GU oncology, the pivotal denosumab 103 trial, GETUG 13, LATITUDE in 2017 showing the impact of abiraterone in de novo metastatic prostate cancer, the ARAMIS Phase 3 study of darolutamide in non-metastatic castration-resistant prostate cancer, the PEACE-1 trial 2021, and the TRITON-3 trial in 2023 showing the role of rucaparib in mCRPC.
In 2013, Prof. Fizazi established the Prostate Cancer Consortium in Europe (PEACE); and is leading several large European Phase III trials, PEACE-1, PEACE-2 and the ongoing PEACE-4.
Prof. Fizazi is the president of the French Groupe d’Etude des Tumeurs Genito-Urinaires(GETUG). He is the Associate Editor of the European Journal of Cancer and has authored almost 500 scientific publications.
